Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska, T., Johnson, E., Kontro, M., Repasky, G.A., Chen, J., Wells, P., Cronin, C.N., McTigue, M., Kallioniemi, O., Porkka, K., Murray, B.W., Wennerberg, K.(2015) Nature 519: 102-105
- PubMed: 25686603 
- DOI: 10.1038/nature14119
- Primary Citation of Related Structures:  
4TWP, 4WA9 - PubMed Abstract: 
The BCR-ABL1 fusion gene is a driver oncogene in chronic myeloid leukaemia and 30-50% of cases of adult acute lymphoblastic leukaemia. Introduction of ABL1 kinase inhibitors (for example, imatinib) has markedly improved patient survival, but acquired drug resistance remains a challenge ...